Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

被引：0
作者：
G L Ceresoli
P A Zucali
M Mencoboni
M Botta
F Grossi
D Cortinovis
N Zilembo
C Ripa
M Tiseo
A G Favaretto
H Soto-Parra
F De Vincenzo
A Bruzzone
E Lorenzi
L Gianoncelli
B Ercoli
L Giordano
A Santoro
机构：
[1] Cliniche Humanitas Gavazzeni,Department of Medical Oncology
[2] Humanitas Cancer Center,Department of Oncology
[3] Ospedale Villa Scassi,Department of Oncology
[4] Sampierdarena,Department of Medical Oncology
[5] ASL 3 Genovese,Department of Medical Oncology
[6] Ospedale S. Spirito,Department of Medical Oncology
[7] Lung Cancer Unit,Department of Medical Oncology
[8] National Institute for Cancer Research,Department of Medical Oncology
[9] Ospedale San Gerardo,Department of Medical Oncology
[10] National Cancer Institute,undefined
[11] Ospedale Maggiore,undefined
[12] Istituto Oncologico Veneto IRCCS,undefined
[13] Ospedale Universitario Vittorio Emanuele,undefined
[14] Biostatistic Unit,undefined
[15] Humanitas Cancer Center,undefined
来源：
British Journal of Cancer | 2013年 / 109卷
关键词：
mesothelioma; bevacizumab; chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：552 / 558
页数：6
相关论文
共 275 条
[1]  
Abu-Hejleh T(2012)Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers Curr Oncol Rep 14 277-284
[2]  
Mezhir JJ(2011)A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy J Clin Oncol 29 7006-260
[3]  
Goodheart JJ(2004)Modified RECIST criteria for assessment of response in malignant pleural mesothelioma Ann Oncol 15 257-307
[4]  
Halfdanarson TR(2011)Molecular mechanisms and clinical application of angiogenesis Nature 473 298-373
[5]  
Baas P(2008)Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM) Ann Oncol 19 370-1448
[6]  
Buikhuisen W(2006)Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma J Clin Oncol 24 1443-32
[7]  
Dalesio O(2010)Second-line treatment for malignant pleural mesothelioma Cancer Treat Rev 36 24-844
[8]  
Vincent A(2012)Anti-angiogenic therapies for malignant pleural mesothelioma Expert Opin Investig Drugs 21 833-220
[9]  
Pavlakis N(1972)Regression models and life tables J R Stat Soc B 34 187-152
[10]  
Van Klaveren R(1998)Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 145-571
12345678910